Latest Ratios: P/E Ratio -1.6x · EV/EBITDA N/A · ROE -132.6%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $313M | $278M | $237M | $200M | $106M | $185M | $254M | $123M | $160M | $127M | $87M |
| Enterprise Value | $232M | $197M | $209M | $179M | $85M | $121M | $193M | $122M | $131M | $106M | $58M |
| P/E Ratio → | -1.61 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 3.42 | 3.56 | 1.38 | 2.44 | 0.96 | 2.88 | 2.84 | — | 1.71 | 1.62 | 0.71 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -132.6% | -132.6% | -63.6% | -38.4% | -40.3% | -65.7% | -95.1% | -50.0% | -71.6% | -52.0% | -39.8% |
| ROA | -95.7% | -95.7% | -54.4% | -33.2% | -34.5% | -55.2% | -77.0% | -36.4% | -54.0% | -43.9% | -36.1% |
| ROIC | -184.2% | -184.2% | -66.8% | -41.8% | -61.0% | -266.7% | -242.7% | -55.3% | -77.1% | -53.7% | -36.8% |
| ROCE | -134.3% | -134.3% | -69.3% | -41.3% | -39.4% | -61.0% | -90.1% | -43.1% | -60.7% | -49.0% | -38.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.03 | 0.07 | 0.05 | 0.09 | 0.07 | — | 0.22 | 0.26 | 0.03 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.04 | -0.16 | -0.26 | -0.19 | -1.00 | -0.69 | — | -0.31 | -0.27 | -0.24 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | -54.34 | -166.14 |
Net cash position: cash ($85M) exceeds total debt ($4M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.19 | 2.19 | 8.02 | 9.49 | 11.28 | 8.16 | 10.89 | 0.81 | 9.12 | 14.39 | 13.23 |
| Quick Ratio | 2.19 | 2.19 | 8.02 | 9.49 | 11.28 | 8.16 | 10.89 | 0.81 | 9.12 | 14.39 | 13.23 |
| Cash Ratio | 2.11 | 2.11 | 7.53 | 9.13 | 11.06 | 7.92 | 10.30 | 0.17 | 8.87 | 13.99 | 13.06 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 42.1% | 0.2% | 0.3% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 42.1% | 0.2% | 0.3% |
| Shares Outstanding | — | $73M | $61M | $44M | $26M | $17M | $12M | $9M | $3M | $2M | $2M |
Clinical Trial Regulatory Failure
As reported in financial statements, Larimar's price-to-book ratio of 3.42 reflects a market valuation heavily predicated on the potential success of its CTI-1601 pipeline, rather than current earnings, which remain negative with a TTM P/E of -1.61, signaling a high-risk, high-reward growth-oriented market pricing model.
The current valuation multiple suggests that investors are pricing in a significant probability of regulatory approval for the company's lead asset. Given the absence of revenue, traditional P/E metrics are non-informative, and the P/B ratio serves as the primary gauge of how much premium the market assigns to the company's intellectual property and clinical data relative to its tangible capital base.
Based on quarterly data, Larimar's ROIC has consistently remained in negative territory, reaching -192.1% in 2025Q4, which illustrates the substantial capital intensity required to fund the development of its proprietary cell-penetrating peptide platform before any commercialization or revenue generation can occur to offset these costs.
The persistent decay in return on invested capital is a structural feature of a pre-revenue biotech firm, where every dollar of capital deployed is directed toward R&D rather than productive assets. Investors should monitor whether the eventual transition to commercialization can reverse this trend, as the current negative returns are a direct consequence of the high-cost, long-duration nature of clinical trials.
According to recent SEC filings, Larimar's current ratio of 4.29 in 2026Q1 indicates a comfortable short-term liquidity position, yet this metric is highly volatile, having fluctuated significantly from a peak of 17.99 in 2024Q1 as the company periodically taps equity markets to sustain its high cash burn.
While the current ratio suggests the company can meet its immediate obligations, the reliance on external equity financing means that liquidity is not self-sustaining. The rapid depletion of cash reserves between financing rounds warrants close attention, as any delay in clinical milestones could force the company to raise capital under less favorable market conditions.
As noted in financial analysis, the use of net margin or P/E ratios to evaluate Larimar is fundamentally flawed, as these metrics obscure the company's status as a clinical-stage entity where R&D spending is an investment in future value rather than a sign of operational inefficiency.
Investors should instead focus on the cash burn rate and the progress of clinical trial milestones, as these are the true drivers of value for a single-asset biotech. Applying standard profitability ratios to a company that has not yet commercialized a product leads to misleading conclusions about its long-term viability and competitive strength.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LRMR stock.
Larimar Therapeutics, Inc.'s current P/E ratio is -1.6x. This places it at the 50th percentile of its historical range.
Larimar Therapeutics, Inc.'s return on equity (ROE) is -132.6%. The historical average is -70.9%.
Based on historical data, Larimar Therapeutics, Inc. is trading at a P/E of -1.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.